NOV - NOV Inc.
NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn's Disease (FSCD). Approximately 46% of Crohn's disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery.
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) will hold a conference call to discuss its second quarter 2026 results on Wednesday, July 29, 2026, at 10 a.m. (Central Time).
NOV shares rise 32% over the past six months as offshore demand, backlog growth and efficiency gains boost prospects despite tariffs and risks.
Nov Inc. (NOV) reported earnings 30 days ago. What's next for the stock?
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.09 per share of common stock, payable on June 26, 2026 to each stockholder of record on June 12, 2026.
SEI's Q1 profit jumped 120%, and revenues rose 55% as Power Solutions scaled, aided by behind-the-meter data center power demand.
NOV Q1 earnings miss estimates as Middle East disruptions hit operations, while revenues edge past expectations despite a year-over-year decline.
The war with Iran has boosted prices of globally traded natural gas by throttling exports from the Gulf. In West Texas, gas is so abundant that some producers must pay to have it taken away.
NOV Inc. (NOV) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Nov Inc. (NOV) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Nov Inc. (NOV) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.19 per share a year ago.
*Free Cash Flow, Excess Free Cash Flow, Adjusted Operating Profit, and Adjusted EBITDA are non-GAAP measures, see “Non-GAAP Financial Measures,” and “Reconciliation of GAAP to non-GAAP measures” below.
Revenues of $2. 05 billion Net income of $19 million, or $0. 05 per share Adjusted EBITDA* of $177 million Bookings of $520 million, representing a book-to-bill of 80% Returned $100 million of capital to shareholders through share repurchases and dividends *Free Cash Flow, Excess Free Cash Flow, Adjusted Operating Profit, and Adjusted EBITDA are non-GAAP measures, see "Non-GAAP Financial Measures," and "Reconciliation of GAAP to non-GAAP measures" below.
NOV faces Q1 pressure as disruptions, weak drilling demand and cost inflation weigh despite offshore strength and backlog offering potential upside.
Nov Inc. (NOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NOV expects weaker Q1 results as Middle East conflict delays deliveries, raises costs and pressures margins despite stable global operations.
HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) announced today that operational disruptions resulting from the war in the Middle East will cause first quarter 2026 revenue and earnings to be below prior guidance. On a consolidated basis, the Company currently expects to report revenues of $2.05 billion, operating profit of $47 million, and Adjusted EBITDA* of $177 million.
NOV Inc. (NYSE: NOV - Get Free Report) was the target of some unusual options trading on Wednesday. Traders bought 2,616 put options on the company. This represents an increase of 1,353% compared to the typical volume of 180 put options. Analysts Set New Price Targets A number of analysts have recently commented on NOV shares.
NOV shows strong cash flow, balance sheet strength and offshore growth prospects, but faces headwinds from weak wind demand, declining margins and softer global drilling activity.